Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama. more
Time Frame | SER | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.59% | -3.39% | 0.2% |
1-Month Return | -4.2% | -1.92% | 2.72% |
3-Month Return | -20.96% | -10.54% | 7.31% |
6-Month Return | -62.58% | -4.47% | 10.44% |
1-Year Return | -63.31% | 4.06% | 27.53% |
3-Year Return | -77.95% | 0.94% | 30.88% |
5-Year Return | -90.22% | 36.67% | 89.21% |
10-Year Return | -95.13% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.73M | 54.00K | 3.04M | 500.00K | 142.00K | [{"date":"2019-12-31","value":56.86,"profit":true},{"date":"2020-12-31","value":1.78,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":16.45,"profit":true},{"date":"2023-12-31","value":4.67,"profit":true}] |
Cost of Revenue | 998.50K | 1.28M | 150.00K | 145.00K | 171.00K | [{"date":"2019-12-31","value":77.95,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":11.71,"profit":true},{"date":"2022-12-31","value":11.32,"profit":true},{"date":"2023-12-31","value":13.35,"profit":true}] |
Gross Profit | 729.50K | (1.23M) | 2.89M | 355.00K | (29.00K) | [{"date":"2019-12-31","value":25.25,"profit":true},{"date":"2020-12-31","value":-42.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":12.29,"profit":true},{"date":"2023-12-31","value":-1,"profit":false}] |
Gross Margin | 42.22% | (2272.22%) | 95.06% | 71.00% | (20.42%) | [{"date":"2019-12-31","value":44.41,"profit":true},{"date":"2020-12-31","value":-2390.19,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":74.69,"profit":true},{"date":"2023-12-31","value":-21.48,"profit":false}] |
Operating Expenses | 13.29M | 9.18M | 4.67M | 2.77M | 9.93M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":69.08,"profit":true},{"date":"2021-12-31","value":35.15,"profit":true},{"date":"2022-12-31","value":20.85,"profit":true},{"date":"2023-12-31","value":74.73,"profit":true}] |
Operating Income | (12.56M) | (10.41M) | (1.63M) | (2.27M) | (9.96M) | [{"date":"2019-12-31","value":-1255900000,"profit":false},{"date":"2020-12-31","value":-1040700000,"profit":false},{"date":"2021-12-31","value":-163150800,"profit":false},{"date":"2022-12-31","value":-227036800,"profit":false},{"date":"2023-12-31","value":-996000000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | 374.57K | (425.86K) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-113.69,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (12.24M) | (10.40M) | (1.26M) | (2.68M) | (14.81M) | [{"date":"2019-12-31","value":-1223600000,"profit":false},{"date":"2020-12-31","value":-1039900000,"profit":false},{"date":"2021-12-31","value":-126470300,"profit":false},{"date":"2022-12-31","value":-268210800,"profit":false},{"date":"2023-12-31","value":-1481100000,"profit":false}] |
Income Taxes | 148.00K | 466.00K | 3.09K | (250.04K) | (8.00K) | [{"date":"2019-12-31","value":31.76,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.66,"profit":true},{"date":"2022-12-31","value":-53.66,"profit":false},{"date":"2023-12-31","value":-1.72,"profit":false}] |
Income After Taxes | - | - | (1.27M) | (2.43M) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-126779700,"profit":false},{"date":"2022-12-31","value":-243207000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | - | - | (1.26M) | (2.68M) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-126470300,"profit":false},{"date":"2022-12-31","value":-268210800,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (12.15M) | (10.87M) | (1.26M) | (2.68M) | (14.80M) | [{"date":"2019-12-31","value":-1215400000,"profit":false},{"date":"2020-12-31","value":-1086500000,"profit":false},{"date":"2021-12-31","value":-126470300,"profit":false},{"date":"2022-12-31","value":-268210800,"profit":false},{"date":"2023-12-31","value":-1480300000,"profit":false}] |
EPS (Diluted) | (11.48) | (10.14) | (8.05) | (9.70) | (13.72) | [{"date":"2019-12-31","value":-1147.79,"profit":false},{"date":"2020-12-31","value":-1014.45,"profit":false},{"date":"2021-12-31","value":-805.28,"profit":false},{"date":"2022-12-31","value":-969.69,"profit":false},{"date":"2023-12-31","value":-1371.85,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SER | |
---|---|
Cash Ratio | 0.24 |
Current Ratio | 0.40 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SER | |
---|---|
ROA (LTM) | -45.29% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SER | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 2.86 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -1.85 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SER | |
---|---|
Trailing PE | 46.00 |
Forward PE | NM |
P/S (TTM) | 18.03 |
P/B | 0.00 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 40.08 |
Serina Therapeutics Inc (SER) share price today is $5.945
Yes, Indians can buy shares of Serina Therapeutics Inc (SER) on Vested. To buy Serina Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SER stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Serina Therapeutics Inc (SER) via the Vested app. You can start investing in Serina Therapeutics Inc (SER) with a minimum investment of $1.
You can invest in shares of Serina Therapeutics Inc (SER) via Vested in three simple steps:
The 52-week high price of Serina Therapeutics Inc (SER) is $22.32. The 52-week low price of Serina Therapeutics Inc (SER) is $3.81.
The price-to-earnings (P/E) ratio of Serina Therapeutics Inc (SER) is 46
The price-to-book (P/B) ratio of Serina Therapeutics Inc (SER) is 0.00
The dividend yield of Serina Therapeutics Inc (SER) is 0.00%
The market capitalization of Serina Therapeutics Inc (SER) is $57.20M
The stock symbol (or ticker) of Serina Therapeutics Inc is SER